Biotech News

Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan

Coherus BioSciences, Inc. (CHRS)Coherus BioSciences, Inc.Earnings

– Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development – – Deprioritize development of tagmokitug/toripalimab in other indications to allocate resources toward advancing the lead indication – –

Related news

Coherus BioSciences, Inc.

Immuno-Oncology Portfolio Coherus Oncology develops antibody-based cancer therapies intended to overcome immune suppression in the tumor microenvironment. Its pipeline combines internally controlled candidates with toripalimab, marketed in the United States as LOQTORZI. Casdozokitug Casdozokitug is an anti-IL-27 antibody being studied...

Recent company news

Stock data

Close
0.39 USD
Market cap
234.46M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States